Gene and cell therapy using cell fusion technology
US-11998617-B2 · Jun 4, 2024 · US
US10426801B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10426801-B2 |
| Application number | US-201414256777-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 18, 2014 |
| Priority date | Oct 18, 2011 |
| Publication date | Oct 1, 2019 |
| Grant date | Oct 1, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A therapeutic or diagnostic delivery vehicle is provided. The delivery vehicle may include one or more particles, such as microparticles, nanoparticles and stimuli-responsive particles, conjugated to a tropic cell that targets at least one pathological entity or site. In addition, a pharmaceutical composition is provided. The pharmaceutical composition may include, among other things, a particle conjugated to a tropic cell such as those discussed above and at least one diagnostic or therapeutic agent, such as those described herein. In some aspects, the tropic cell may target at least one pathological entity or site. Further, methods for diagnosing, monitoring or treating a pathological condition in a subject are provided. Such methods may include administering a therapeutically effective amount of the pharmaceutical composition to a subject.
Opening claim text (preview).
What is claimed is: 1. A therapeutic delivery vehicle comprising a gold particle coated with a cationic thiol moiety internalized by a genetically modified neural stem cell, wherein the cationic thiol moiety is 11-mercaptoundecyltrimethylammonium bromide. 2. The therapeutic delivery vehicle of claim 1 , wherein the genetically modified neural stem cell is an immortalized neural stem cell. 3. The therapeutic delivery vehicle of claim 1 , wherein the genetically modified neural stem cell expresses cytosine deaminase, v-myc, or both cytosine deaminase and v-myc. 4. The therapeutic delivery vehicle of claim 1 , wherein the gold particle is a gold nanorod. 5. The therapeutic delivery vehicle of claim 1 , wherein the average longest dimension of the gold particle is about 41 nm. 6. The therapeutic delivery vehicle of claim 1 , wherein the gold particle is about 10 nm by about 41 nm.
conjugated systems · CPC title
the form being a nanoparticle, e.g. an immuno-nanoparticle · CPC title
Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors · CPC title
Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue · CPC title
the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.